menu
    • menu

    Find Albiglutide manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 1
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    0

    USDMF

    0

    CEP/COS

    0

    JDMF

    0

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    0

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    1

    FDA Orange Book

    2

    Europe

    0

    Canada

    0

    Australia

    0

    South Africa

    0

    Listed Dossiers

    1PROSPECTS

    20DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    47RELATED EXCIPIENT COMPANIES

    104EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    2

    Health Canada Patents
    API/FDF Prices: Book a Demo

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    314

    Regulatory FDF Prices

    NA

    MARKET PLACE

    0

    API

    1

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    2

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Chebi:78425, Chebi:136045
    Molecular Formula
    C148H223N39O46
    Molecular Weight
    3284.6  g/mol
    InChI Key
    OGWAVGNOAMXIIM-VTAHJYCESA-N
    Albiglutide
    1 2D Structure

    Albiglutide

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
    2.1.2 InChI
    InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1
    2.1.3 InChI Key
    OGWAVGNOAMXIIM-VTAHJYCESA-N
    2.1.4 Canonical SMILES
    CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CNC=N6)N
    2.1.5 Isomeric SMILES
    CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. Chebi:78425

    2. Chebi:136045

    2.3 Create Date
    2016-10-14
    3 Chemical and Physical Properties
    Molecular Weight 3284.6 g/mol
    Molecular Formula C148H223N39O46
    XLogP3-14
    Hydrogen Bond Donor Count49
    Hydrogen Bond Acceptor Count51
    Rotatable Bond Count109
    Exact Mass3283.6342956 g/mol
    Monoisotopic Mass3282.6309408 g/mol
    Topological Polar Surface Area1380 Ų
    Heavy Atom Count233
    Formal Charge0
    Complexity7620
    Isotope Atom Count0
    Defined Atom Stereocenter Count29
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 10, 2017

    blank

    01

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects Wit...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    January 10, 2017

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Albiglutide,Exenatide

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Protein

    Sponsor: Massachusetts General Hospital

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 16, 2016

    blank

    02

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Exenatide

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Massachusetts General Hospital

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to N...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    June 16, 2016

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mell...

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 26, 2016

    blank

    03

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of A...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    April 26, 2016

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 17, 2016

    blank

    04

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    February 17, 2016

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 21, 2016

    blank

    05

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    January 21, 2016

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Cholecystokinin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 14, 2015

    blank

    06

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Cholecystokinin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    July 14, 2015

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Protein

    Sponsor: Duke Clinical Research Institute

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 08, 2015

    blank

    07

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Duke Clinical Research Institute

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovas...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    June 08, 2015

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.


    Lead Product(s): Albiglutide,Insulin

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 05, 2014

    blank

    08

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Insulin

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    November 05, 2014

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: PPD

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 01, 2014

    blank

    09

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : PPD

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Sub...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    September 01, 2014

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

    Details:

    Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Albiglutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: PPD

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 01, 2014

    blank

    10

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Albiglutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : PPD

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabete...

    Details : Albiglutide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    September 01, 2014

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    GSK

    United Kingdom
    PharmaSynergy
    Not Confirmed
    arrow

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    ALBIGLUTIDE

    Brand Name : TANZEUM

    Dosage Form : INJECTABLE;INJECTION

    Dosage Strength : 30MG

    Packaging :

    Approval Date :

    Application Number : 125431

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    GSK

    United Kingdom
    PharmaSynergy
    Not Confirmed
    arrow

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Albiglutide

    Brand Name : Eperzan

    Dosage Form : Solution For Injection

    Dosage Strength : 30mg

    Packaging :

    Approval Date : 21/03/2014

    Application Number : 20130312000116

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    GSK

    United Kingdom
    PharmaSynergy
    Not Confirmed
    arrow

    GSK

    United Kingdom
    arrow
    PharmaSynergy
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Albiglutide

    Brand Name : Eperzan

    Dosage Form : Solution For Injection

    Dosage Strength : 50mg

    Packaging :

    Approval Date : 21/03/2014

    Application Number : 20130312000123

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Topical

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for / Albiglutide API manufacturers, exporters & distributors?

    Albiglutide manufacturers, exporters & distributors 1

    86

    PharmaCompass offers a list of Albiglutide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Albiglutide manufacturer or Albiglutide supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Albiglutide manufacturer or Albiglutide supplier.

    PharmaCompass also assists you with knowing the Albiglutide API Price utilized in the formulation of products. Albiglutide API Price is not always fixed or binding as the Albiglutide Price is obtained through a variety of data sources. The Albiglutide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Albiglutide

    Synonyms

    Chebi:78425, Chebi:136045

    Albiglutide Manufacturers

    A Albiglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Albiglutide, including repackagers and relabelers. The FDA regulates Albiglutide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Albiglutide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    Albiglutide Suppliers

    A Albiglutide supplier is an individual or a company that provides Albiglutide active pharmaceutical ingredient (API) or Albiglutide finished formulations upon request. The Albiglutide suppliers may include Albiglutide API manufacturers, exporters, distributors and traders.

    Albiglutide GMP

    Albiglutide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Albiglutide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Albiglutide GMP manufacturer or Albiglutide GMP API supplier for your needs.

    Albiglutide CoA

    A Albiglutide CoA (Certificate of Analysis) is a formal document that attests to Albiglutide's compliance with Albiglutide specifications and serves as a tool for batch-level quality control.

    Albiglutide CoA mostly includes findings from lab analyses of a specific batch. For each Albiglutide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Albiglutide may be tested according to a variety of international standards, such as European Pharmacopoeia (Albiglutide EP), Albiglutide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Albiglutide USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search